False elevation of human chorionic gonadotropin in a patient with testicular cancer

Nature Reviews Urology

Volumn 7, Issue 4, 2010, Pages 230-233

  Gallagher, David J ^a   Riches, Jamie ^a   Bajorin, Dean F ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CHORIONIC GONADOTROPIN; CISPLATIN; COTRIMOXAZOLE; ETOPOSIDE; FOLLITROPIN; HETEROPHILE ANTIBODY; LACTATE DEHYDROGENASE; LUTEINIZING HORMONE; TESTOSTERONE CIPIONATE;

ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CANCER REGRESSION; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; FALSE POSITIVE RESULT; HORMONE DETERMINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOASSAY; MALE; MULTIPLE CYCLE TREATMENT; ORCHIECTOMY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCROTAL SWELLING; STAPHYLOCOCCUS AUREUS; SUPPURATIVE HIDRADENITIS; SURGICAL DRAINAGE; TESTIS CANCER; TREATMENT RESPONSE;

ADULT; ANTIBODIES, HETEROPHILE; ANTINEOPLASTIC AGENTS; CHORIONIC GONADOTROPIN; FALSE POSITIVE REACTIONS; HUMANS; MALE; TESTICULAR NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 77950982161     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2010.10     Document Type: Article

References (24)

1. esfandiari, N. & Goldberg, J. M. Heterophile antibody blocking agent to confirm false positive serum human chorionic gonadotropin assay. Obstet. Gynecol. 101, 1144-1146 (2003). (Pubitemid 36566408)
2. Garnick, M. B. Spurious rise in human chorionic gonadotropin induced by marihuana in patients with testicular cancer. N. Engl. J. Med. 303, 1177 (1980).
3. Buckner, C. L., Wilson, L. & Papadea, C. N. An unusual cause of elevated serum totalβhCG. Ann. Clin. Lab. Sci. 37, 186-191 (2007).
4. Willman, J. H. et al. Multiplex analysis of heterophil antibodies in patients with indeterminate HIV immunoassay results. Am. J. Clin. Pathol. 115, 764-769 (2001).
5. Vidrih, J. A., Walensky, R. P., Sax, P. e. & Freedberg, K. A. Positive epstein-Barr virus heterophile antibody tests in patients with primary human immunodeficiency virus infection. Am. J. Med. 111, 192-194 (2001). (Pubitemid 32786946)
6. Kricka, L. J., Schmerfeld-Pruss, D., Senior, M., Goodman, D. B. & Kaladas, P. Interference by human anti-mouse antibody in two-site immunoassays. Clin. Chem. 36, 892-894 (1990). (Pubitemid 20189260)
7. Azinovic, I. et al. Survival benefit associated with human anti-mouse antibody (HAMA) in patients with B-cell malignancies. Cancer Immunol. Immunother. 55, 1451-1458 (2006). (Pubitemid 44327834)
8. Fritz, B. e., Hauke, R. J. & Stickle, D. F. New onset of heterophilic antibody interference in prostate-specific antigen measurement occurring during the period of postprostatectomy prostate-specific antigen monitoring. Ann. Clin. Biochem. 46, 253-256 (2009).
9. Morgan, B. R. & Tarter, T. H. Serum heterophile antibodies interfere with prostate specific antigen test and result in over treatment in a patient with prostate cancer. J. Urol. 166, 2311-2312 (2001).
10. Park, S., Wians, F. H. Jr & Cadeddu, J. A. Spurious prostate-specific antigen (PSA) recurrence after radical prostatectomy: interference by human antimouse heterophile antibodies. Int. J. Urol. 14, 251-253 (2007). (Pubitemid 46423246)
11. Davis, B. e., Herr, H. W., Fair, W. R. & Bosl, G. J. The management of patients with nonseminomatous germ cell tumors of the testis with serologic disease only after orchiectomy. J. Urol. 152, 111-113 (1994).
12. Culine, S., Theodore, C., Terrier-Lacombe, M. J. & Droz, J. P. Primary chemotherapy in patients with nonseminomatous germ cell tumors of the testis and biological disease only after orchiectomy. J. Urol. 155, 1296-1298 (1996). (Pubitemid 26081222)
13. National Comprehensive Cancer Network Clinical Practice Guidelines in OncologyTM V.2.2009.
14. Loehrer, P. J. Sr, Johnson, D., elson, P., einhorn, L. H. & Trump, D. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an eastern Cooperative Oncology Group trial. J. Clin. Oncol. 13, 470-476 (1995).
15. de Wit, R. et al. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the european Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J. Clin. Oncol. 15, 1837-1843 (1997). (Pubitemid 27209512)
16. einhorn, L. H. et al. evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. J. Clin. Oncol. 7, 387-391 (1989).
17. Culine, S. et al. Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GeTUG T93BP). Ann. Oncol. 18, 917-924 (2007). (Pubitemid 47054091)
18. Travis, L. B. et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J. Natl Cancer Inst. 97, 1354-1365 (2005).
19. Kondagunta, G. V. et al. etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors. J. Clin. Oncol. 23, 9290-9294 (2005). (Pubitemid 46260186)
20. Motzer, R. J. et al. Salvage chemotherapy for patients with germ cell tumors. The Memorial Sloan-Kettering Cancer Center experience (1979-1989). Cancer 67, 1305-1310 (1991).
21. Kondagunta, G. V. et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J. Clin. Oncol. 23, 6549-6555 (2005).
22. einhorn, L. H. et al. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N. Engl. J. Med. 357, 340-348 (2007).
23. Motzer, R. J. et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J. Clin. Oncol. 25, 247-256 (2007).
24. Saxman, S. B. et al. The management of patients with clinical stage I nonseminomatous testicular tumors and persistently elevated serologic markers. J. Urol. 155, 587-589 (1996). (Pubitemid 26023549)